Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

Ajoy Dias, Saad Kenderian, Gustavo F. Westin, Mark R Litzow

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalCurrent Hematologic Malignancy Reports
Volume11
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Therapeutics
Antigens
Survival

Keywords

  • Acute lymphoblastic leukemia (ALL)
  • Chimeric antigen receptor T cells (CART)
  • Immunotherapies
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. / Dias, Ajoy; Kenderian, Saad; Westin, Gustavo F.; Litzow, Mark R.

In: Current Hematologic Malignancy Reports, Vol. 11, No. 4, 01.08.2016, p. 253-264.

Research output: Contribution to journalReview article

@article{c40b576bfe9a4e8487f0ccaed1730fd2,
title = "Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia",
abstract = "Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 {\%}. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.",
keywords = "Acute lymphoblastic leukemia (ALL), Chimeric antigen receptor T cells (CART), Immunotherapies, Monoclonal antibodies",
author = "Ajoy Dias and Saad Kenderian and Westin, {Gustavo F.} and Litzow, {Mark R}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11899-016-0326-1",
language = "English (US)",
volume = "11",
pages = "253--264",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

AU - Dias, Ajoy

AU - Kenderian, Saad

AU - Westin, Gustavo F.

AU - Litzow, Mark R

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.

AB - Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.

KW - Acute lymphoblastic leukemia (ALL)

KW - Chimeric antigen receptor T cells (CART)

KW - Immunotherapies

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84964389013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964389013&partnerID=8YFLogxK

U2 - 10.1007/s11899-016-0326-1

DO - 10.1007/s11899-016-0326-1

M3 - Review article

C2 - 27101015

AN - SCOPUS:84964389013

VL - 11

SP - 253

EP - 264

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 4

ER -